With the HeartMate 3™ LVAD, you can
make a meaningful difference in patient lives.

How your patients live their lives depends on the LVAD you choose. The HeartMate 3 LVAD can now be used for advanced heart failure patients needing short- or long-term mechanical circulatory support (e.g., bridge to transplant (BTT) or myocardial recovery, or destination therapy (DT)).

HeartMate 3 LVAD delivers unprecedented* survival and safety outcomes as demonstrated in the MOMENTUM 3 Trial at two years.1**

83%
Survival

Comparable to
heart transplant survival
at 2 years2
10%
Stroke

The lowest published
stroke rate for
continuous-flow LVADs1,3-6​
1%
Thrombosis

The lowest published
thrombosis rate for
continuous-flow LVADs1,3-6​

outcomes made possible by Full MagLev™ Flow Technology

Full MagLev Flow Technology maintains gentle blood handling to minimize complications and reduce hemocompatibility-related adverse events.

  • Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings.
  • Large, consistent blood flow pathways to reduce shear stress7
  • Intrinsic pulsatility to reduce stasis and minimize thrombus7,8
HeartMate 3 MagLev Technology

Heartmate 3 LVAD Makes A Real Difference In Patients’ Lives

Significant improvements in NYHA class, 6-minute walk distance, and quality of life1

More than 78% of patients improved to NYHA Class I/II from NYHA Class IIIB/IV by 6 months, with sustained improvement in 79% of patients through 2 years (P<0.0001).1

Significant improvements in NYHA Class, 6-minute walk distance, and quality of life

Significant increase in 6-minute walk distance1

At baseline, tested patients completed the 6-minute walk test at an average of 154 meters. At 2 years after HeartMate 3™ LVAD implant, patients completed the test at an average of 308 meters (P<0.0001).1

Football field graphic showing 6 minute walk distance

Meaningful Improvement in quality of life1

28 point improvement
KCCQ Bar Chart

* Based on HeartMate™ LVAD highest published survival and lowest published stroke and thrombosis rates in continuous-flow LVAD category of devices in the U.S.1,3-6
** HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.

Indications and Important Safety Information

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure.

Contraindications: The HeartMate 3™ Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulationtherapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3™ Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or device thrombosis.

References: 1. Mehra MR, Goldstein DJ, Uriel N, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018;378(15):1386-1395.  2. Lund LF, Khush KK, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report—2017; Focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36:1037-1046.  3. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.  4. Rogers JG, Pagani FD, Tootles AJ, et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. N Engl J Med. 2017;376,451-60.  5. Starling RC, Estep JD, Horstmanshof DA, et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. J Am Coll Cardiol HF. 2017;5:518-527.  6. Jorde UP, Kushwaha SS, Tootles AJ, et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-1757.  7. Bourque K, Cotter C, Dague C, et al. Design Rationale and Preclinical Evaluation of the HeartMate 3 Left Ventricular Assist System for Hemocompatibility. American Society of Artificial Internal Organs. 2016;62:375–383.  8. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.